Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge
暂无分享,去创建一个
Y. Ramot | M. Wiebe | A. Makovitzki | M. Saloheimo | H. Marcus | A. Nyska | M. Aftalion | D. Gur | H. Tamir | Y. Yahalom-Ronen | M. Vitikainen | Noam Kronfeld | T. Holtzman | D. Zarling | S. Ehrlich | Anne Huuskonen | Lilach Cherry | Y. Ophir | Eyal Dor | Edith Lupu | Mark Emalfarb | R. Tchelet | A. Vallerga | Idan Hefetz | Shani Pitel | Ram Nechooshtan | Yehuda Sapir | Moshe Aftalion | David Gur | Tzvi Holtzman
[1] Y. Ramot,et al. Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform , 2022, Toxicologic pathology.
[2] M. Alfenito,et al. The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines , 2022, Vaccines.
[3] William T. Harvey,et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism , 2022, medRxiv.
[4] Jie Zhou,et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry , 2022 .
[5] A. Hernandez,et al. A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice , 2022, Vaccine.
[6] Heidi Ledford,et al. How COVID vaccines shaped 2021 in eight powerful charts , 2021, Nature.
[7] S. Reardon. Cuba’s bet on home-grown COVID vaccines is paying off , 2021, Nature.
[8] G. Chinea,et al. In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum , 2021, Analytical and Bioanalytical Chemistry.
[9] D. Vaughn,et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 , 2021, npj Vaccines.
[10] Jinghua Yan,et al. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants , 2021, Nature Communications.
[11] Neil C. Dalvie,et al. A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates , 2021, bioRxiv.
[12] Haibo Zhang,et al. Emerging SARS-CoV-2 variants of concern and potential intervention approaches , 2021, Critical Care.
[13] M. Béquet-Romero,et al. The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigen , 2021, medRxiv.
[14] M. Wiebe,et al. Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model , 2021, Vaccines.
[15] Laura E. Crowell,et al. Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered Komagataella phaffii , 2021, bioRxiv.
[16] Yan Liu,et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.
[17] J. Wrammert,et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant , 2021, Cell Host & Microbe.
[18] Esteban Ortiz Prado,et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates , 2021, NPJ vaccines.
[19] N. Patel,et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.
[20] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.
[21] K. Dhama,et al. Recombinant vaccines for COVID-19 , 2020, Human vaccines & immunotherapeutics.
[22] P. Hotez,et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate , 2020, Biochimica et Biophysica Acta (BBA) - General Subjects.
[23] S. Perlman,et al. COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.
[24] R. Varadarajan,et al. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment , 2020, Journal of Biological Chemistry.
[25] P. Hotez,et al. SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice , 2020, bioRxiv.
[26] A. Kamen,et al. Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation , 2020, Vaccines.
[27] Min Zheng,et al. A systematic review of SARS-CoV-2 vaccine candidates , 2020, Signal Transduction and Targeted Therapy.
[28] A. Matsiko. Alum adjuvant discovery and potency , 2020 .
[29] Javier Santos,et al. Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells , 2020, Scientific Reports.
[30] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[31] V. Shinde,et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.
[32] N. Patel,et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.
[33] J. Diedrich,et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, bioRxiv.
[34] Shuwen Liu,et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.
[35] Yuquan Wei,et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.
[36] C. Hallam,et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice , 2020, Nature Communications.
[37] G. Gao,et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS , 2020, Cell.
[38] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[39] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[40] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[41] William J. Liu,et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.
[42] D. Qu,et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement , 2020, Cell Discovery.
[43] P. Zhou,et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 , 2020, Cell.
[44] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[45] Jianqing Xu,et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies , 2020, Cellular & Molecular Immunology.
[46] F. Gao,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.
[47] David I Stuart,et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, bioRxiv.
[48] Wenhui Li,et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement , 2020, bioRxiv.
[49] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[50] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[51] K. Shi,et al. Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.
[52] W. Schrödl,et al. Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain , 2018, BMC Microbiology.
[53] Elissa M. Hudspeth,et al. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate , 2017, Journal of Pharmaceutical Sciences.
[54] S. Reed,et al. Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.
[55] A. Gusakov,et al. Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1 , 2011 .
[56] K. Rock,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.
[57] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[58] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[59] S. Hem,et al. Aluminum Compounds Used as Adjuvants in Vaccines , 1990, Pharmaceutical Research.